Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FINALITY-HF: Finerenone in Heart Failure with Reduced Ejection Fraction
NCT06033950Phase 3Recruiting
- Sponsor
- CPC Clinical Research
- Start
- Aug 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of finerenone in heart failure (HF), sponsored by CPC Clinical Research. Started Aug 2024; status: recruiting.
02
Drugs
finerenone
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT06033950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06033950.